Inverness Medical Innovations Announces Third Quarter 20...(come or loss on an adjusted cash basis ...),Health

Date:10/27/2009

come or loss on an adjusted cash basis" is not a standard financial measurement under accounting principles generally accepted in the United States of America ("GAAP") and should not be considered as an alternative to net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, "net income or loss on an adjusted cash basis" presented in this press release may not be comparable to similar measures used by other companies.

(b) Amortization expense of $65.4 million and $60.0 million in the third quarter of 2009 and 2008 GAAP results, respectively, including $10.3 million and $10.5 million charged to cost of sales, $0.9 million and $1.0 million charged to research and development and $54.0 million and $48.3 million charged to selling, general and administrative, in the respective periods, with $0.2 million charged through equity earnings of unconsolidated entities, net of tax during each of the respective periods.

(c) Restructuring charges associated with the decision to close facilities of $6.2 million and $5.8 million for the third quarter of 2009 and 2008 GAAP results, respectively. The $6.2 million charge for the third quarter of 2009 included $2.6 million charged to cost of sales, $0.1 million charged to research and development, $2.4 million charged to selling, general and administrative, $0.2 million charged to interest expense and $0.9 million charged through equity earnings of unconsolidated entities, net of tax. The $5.8 million charge for the third quarter of 2008 included $1.8 million charged to cost of sales, $0.3 million charged to research and development, $3.4 million charged to selling, general and administrative and $0.3 million charged to interest expense. These charges have been excluded f
'/>"/>

SOURCE Inverness Medical Innovations, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine technology :

1. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
2. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
3. Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit
4. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
5. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
6. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
7. Reportlinker Adds Medical Devices & Equipment in India (2009)
8. ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call
9. Rcadia Medical Imaging Wins 2009 AuntMinnie.com Best New Radiology Vendor Award
10. Cardio Vascular Medical Device Sends Update to Shareholders
11. Symmetry Medical Updates Full Year 2009 Financial Guidance